About this trial
A national, randomized, clinical trial (phase III) investigating radiotherapy with protons compared with photons for patients with squamous cell carcinoma of the head and neck area eligible for radiotherapy, either radical or postoperative, with curative intent. Comparative dose plans with protons and photons will be prepared, and the probability of toxicity evaluated with NTCP models. Patients with presumed benefit from protons will be randomized 1:1 to treatment with protons or photons. The number of randomized participants will be 400. The primary endpoint is "combined toxicity burden" - dry mouth, difficulty swallowing, pain and affected speech in the period after the end of radiotherapy to 12 months after treatment.
Eligibility criteria
Qualifiers
Signed informed consent.
Age ≥ 40 years.
Histological or cytological verified squamous cell carcinoma of the following head and neck regions; oral cavity, oropharynx, hypopharynx or larynx.
Planned for standard radiotherapy with curative intent, either as definitive or postoperative treatment with or without concomitant chemotherapy (cisplatin).
Disqualifiers
Glottic cancers, cT1-T2 cN0 cM0.
Nasopharyngeal carcinomas, sino-nasal cancers, and head and neck salivary gland carcinomas.
Distant metastasis.
Previous radiotherapy to the head and neck.
Trial design
Treatments tested in this trial
- Proton Radiotherapy
Treatment groups
Sponsors and collaborators
Oslo University Hospital
Lead sponsor
Klinbeforsk
Collaborator
South-Eastern Norway Regional Health Authority
Collaborator